/HUMA

Humacyte Inc

HUMA

$0.57USD↑+0.09%+0.00 today

MARKET CAP

157.7M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1

$3

AI Summary

Stalk

Sell NowHigh

HUMA remains in a pronounced Stage 4 downtrend, characterized by a clear sequence of lower highs and lower lows on declining EMAs and a 200 SMA well above price. Trading near its 52-week low with muted volume on rallies, the medium- and long-term bias is strongly bearish. Short-term price action—tightly tracking below the 9- and 20-EMA and resting at an extreme oversold level—suggests selling is warranted now. A decisive close above the 50 SMA would invalidate this bearish view.

↑Interim Phase 3 results pave way for BLA submission later this year
↑Approval could unlock dialysis market revenue in regenerative medicine
↓Earnings yield of -2.85% and weak profitability hinder cash-flow generation

Full analysis →

Buying

6

institutions

Selling

4

institutions

New Positions

3

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	SELL	4.84 M	3.78 M	+-7.48 M	-49.5%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	2.60 M	2.03 M	+672.44 K	+73.6%	0.00%
MM Millennium Management LLC Q2 2026	BUY	1.91 M	1.49 M	+1.80 M	+2170.5%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	1.87 M	1.46 M	+1.47 M	+507.1%	0.00%
WP Woodline Partners LP Q2 2026	SELL	500.58 K	390.65 K	+-3.50 M	-83.9%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUYNEW	53.73 K	41.93 K	+53.73 K	+0.0%	0.00%
PA Polar Asset Management Partners Inc. Q2 2026	BUYNEW	52.60 K	41.05 K	+52.60 K	+0.0%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	BUYNEW	21.61 K	16.86 K	+21.61 K	+0.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	13.59 K	10.86 K	+-67.34 K	-76.7%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	7.00 K	5.46 K	+-3.15 K	-11.3%	0.00%